Spondylitis HLA-B27

Kits: EliGene® Spondylitis HLA-B27 C6 Kit (ref: 90060-C6)
EliGene® Spondylitis HLA-B27 RT Kit (ref: 90060-RT)
Package size:
 192 reactions (EliGene® Spondylitis HLA-B27 C6 Kit)
50 reactions (EliGene® Spondylitis HLA-B27 RT Kit)
Analytical specificity: Allele HLA-B27
Specimens: Blood, buccal swabs
Compatible instruments:
 Real-Time Systems 7000, 7300, 7500 Applied Biosystems, LightCycler® 480, LightCycler® Nano, fully compatible with RotorGene instruments - EliGene® Spondylitis HLA-B27 RT Kit

COBAS® 6800/8800 Systems (Roche) - EliGene® Spondylitis HLA-B27 C6 Kit
CE certification: yes
Detection technology: TaqMan probes
Clinical study description and results:
EliGene® Spondylitis HLA-B27 RT Kit specificity were tested on 100 samples of human DNA with genotypes determined by DNA sequencing. The specificity of the method was validated by searching in the DNA databases as well.
Specificity: 100 %
Description:
Human Leukocyte Antigen (HLA) B27 (subtypes B*2701-2759) is an HLA class I surface antigen that is encoded in the B locus in the major histocompatibility complex (MHC) on the short arm of chromosome 6. In HLA-B27 antigen a strong association with ankylosing spondylitis (AS) and spondyloarthropathies (SpA) was found. Moreover the increased incidence of this antigen in other diseases as Reiter´s syndrome or uveitis was found. Association studies found an association between HLA-B27 antigen and AS in all ethnic and racial groups worldwide however the prevalence of HLA-B27 antigen and the strength of its association with AS does vary. For example, the prevalence of HLA-B27 antigen is about 8% in Caucasians, 4% in North Africans, 2-9% in Chinese, and 0.1-0.5% in Japanese. Further, among northern Europeans only 8% of the general population possesses HLA-B27, but more than 90% of the patients with AS possess this gene. In contrast, among African Americans 2% to 4% of the general population and only 50% to 60% of patients with AS possess this gene. From this reasons HLA-B27 test cannot be used to screen an asymptomatic population to detect AS but the test provides a statement of increased probability of the existence of AS in the symptomatic patient. Also, the presence of HLA-B27 antigen influences the clinical manifestations of AS disesase, because HLA-B27–positive patients have a significantly younger age at onset of their disease and a higher prevalence of episodes of eye inflammation (acute anterior uveitis) and hip joint involvement.
References:
Khan MA. 2010. Remarkable Polymorphism of HLA-B27: An Ongoing Saga. Curr Rheumatol Report. 12: 337-41

Robinson PC, Brown MA. 2012. The genetics of ankylosing spondylitis and axial spondyloarthritis. Rheum Dis Clin North Am. 38(3):539-53

Thomas GP, Brown MA. 2010. Genetics and Genomics of Ankylosing Spondylitis. Immunol Rev. 233:162-180.